Introduction
Functional inactivation of the p53 tumor suppressor protein is observed frequently in human cancers. p53 possesses multiple activities, including transcriptional activation/suppression, nucleic acid modi®cation, and centrosome duplication control (reviewed in Ko and Prives, 1996; Mowat, 1998) . One of the important procarcinogenic phenotypes resulting from p53 inactivation is chromosome instability, which promotes genetic mutations required for acquisition of malignant phenotypes (reviewed in Tarapore and Fukasawa, 2000) . For instance, extensive aneuploidy is observed in cells or tissues derived from p53-null mice (Harvey et al., 1993; Fukasawa et al., 1996 Fukasawa et al., , 1997 , and p53-null mice show accelerated incidence of tumor formation (Donehower et al., 1992; Jacks et al., 1994) . We have previously shown that chromosome instability in p537/7 cells is primarily due to abnormal ampli®ca-tion of centrosomes and the consequential mitotic defects (Fukasawa et al., 1996 (Fukasawa et al., , 1997 .
The centrosome is a major microtubule organizing center of animal cells, and directs bipolar mitotic spindle formation, which is essential for accurate chromosome transmission to daughter cells (for recent reviews, see Urbani and Stearns, 1999; Lange et al., 2000) . Since each daughter cell inherits one centrosome, the centrosome must duplicate prior to the next mitosis, and do so only once. Thus, centrosome duplication must take place in coordination with other cell cycle events, including DNA synthesis. In mammalian cells, the centriole, the core component of the centrosome, initiates duplication in coordination with S phase entry (reviewed in Mazia, 1987; Vandre and Borisy, 1989; Winey, 1996; Sluder and Hinchclie, 2000) . Abrogation of the regulatory mechanism that ensures the coordinated progression of centrosome duplication with other cell cycle events, and that limits centrosome duplication to only once per cell cycle, leads to centrosome hyperampli®cation as depicted in p537/7 cells (reviewed in Winey, 1996; Brinkley and Goepfert; 1998) . The strong correlation between p53 inactivation and the occurrence of centrosome hyperampli®cation has also been reported in various types of human cancers (Weber et al., 1998; Carroll et al., 1999) . We have recently shown that p53 is involved in the regulation of centrosome duplication directly, and not through inducing other mutations, since reintroduction of wild-type p53 into p537/7 cells restores the normal centrosome duplication cycles (Tarapore et al., 2001) .
Inactivation of p53 commonly results from deletion or missense mutation of the p53 gene. For instance, a majority of advanced human tumors have one mutant and one deleted p53 allele, and most of the mutated alleles have missense mutations clustered in the DNA binding domain, which abrogate its sequence-speci®c DNA binding activity and inhibit its transactivation function (Hollstein et al., 1991; Levine et al., 1991) . One of the major transactivation targets of p53 is p21
Waf1/Cip1 (Waf1) (El-Deiry et al., 1993) , which binds to and inhibits the G1/S cyclin-dependent kinase (CDK)-cyclin complexes, including CDK2/cyclin E (Gu et al., 1993; Harper et al., 1993; Xiong et al., 1993) . The CDK2/cyclin E activity is partly regulated by temporal expression of cyclin E, which occurs during late G1 (Ko et al., 1992; Dulic et al., 1992) . CDK2 is also regulated by a variety of CDK inhibitors, including Waf1 (recently reviewed in Sherr and Roberts, 1999) . CDK2/cyclin E is a known kinase complex that induces initiation of DNA synthesis, and more recently been identi®ed as a factor that triggers initiation of centrosome duplication (Hinchclie et al., 1999; Lacey et al., 1999; Okuda et al., 2000) . These ®ndings suggest that the late G1-speci®c activation of CDK2/cyclin E is a key event for the coordinated progression of the centrosome and DNA duplication cycles. Involvement of Waf1 in the regulation of centrosome duplication has been suggested from the observation that the centrosome and DNA duplication cycles are uncoupled in Waf1-de®cient cells . Active role of Waf1 has also been suggested by others in dierent systems (Lacey et al., 1999; Matsumoto et al., 1999; Mantel et al., 1999) . More recently, we have shown that introduction of Waf1 into p537/7 cells partially restores the centrosome duplication cycle (Tarapore et al., 2001) , suggesting that Waf1 is one of the eectors of p53 in the regulation of centrosome duplication. The partial involvement of Waf1 implies that there may be other (perhaps transactivation function-independent) pathway(s), by which p53 controls the centrosome duplication cycle.
There are several`hot spot' residues of p53 that are mutated at a high frequency in human cancers (Hollstein et al., 1991) . These`hot spot' missense mutants are transactivation-negative, hence fail to upregulate Waf1 (Crook and Vousden, 1992) . If p53 controls centrosome duplication in a transactivation function-independent manner, there may be a dierence in the centrosome duplication regulatory activity among these`hot spot' p53 mutants. To test this, we examined two`hot spot' p53 mutants, R175H (Arg 175?His) and R249S (Arg 249?Ser), for their centrosome duplication regulatory activities. We found that expression of R175H exacerbated centrosome abnormality in p537/7 cells, whereas expression of R249S signi®cantly restored the normal centrosome behavior. Moreover, we found that R249S mutant binds to both unduplicated and duplicated centrosomes, similar to wild-type p53. In contrast, R175H failed to associate with unduplicated centrosomes. Since p53 is phosphorylated by CDK2 on Ser 315 (Price et al., 1995; Wang and Prives, 1995) , we also tested the mutants with a substitution mutation at Ser 315 to either Ala (S315A, non-phosphorylatable) or Asp (S315D, mimicking the constitutively phosphorylated form). Unlike the`hot spot' mutants, both S315A and S315D retain transactivation function (Crook et al., 1994; Fuchs et al., 1995) . We found that both mutants associated with duplicated centrosomes. The S315D mutant also associated with unduplicated centrosomes, but not the S315A mutant, indicating that phosphorylation of Ser 315 is critical for p53 to associate with unduplicated centrosomes. We further found that expression of S315D almost completely restored the normal centrosome duplication cycles in p537/7 cells, while expression of S315A resulted in only a partial restoration. Thus, our present studies suggest that both the transactivation function and the unduplicated centrosome-binding activity controlled by Ser 315 phosphorylation are important for the p53-mediated regulation of centrosome duplication.
Results

Establishment of p53 mutant expressing cell lines
p53 regulates the centrosome duplication cycle through multiple pathways (Tarapore et al., 2001) . To gain further insight on the mechanism of the p53-mediated regulation of centrosome duplication, we decided to examine the human p53`hot spot' mutants (R175H and R249S) as well as CDK phosphorylation site mutants (S315A and S315D) for their eect on the centrosome duplication cycle through expression in p53-null cells. Although human cells are most desirable as host cells, currently available p53-null human cells all have undergone extensive culturing. We have previously shown that the extent of centrosome abnormality decreases during prolonged passaging (Chiba et al., 2000) . Since presence of hyperampli®ed centrosomes frequently results in mitotic defects and cell death, the`natural' restoration of centrosome numbers in p537/7 cells during a long term culture is likely due to acquisition of additional mutation(s) that complement the dysregulation of centrosome duplication initially imposed by loss of p53. Since these centrosome duplication-targeted mutations potentially acquired during prolonged passaging may complicate the interpretation of the results, we decided to use p537/7 murine embryonic ®broblasts (MEFs), which can be freshly prepared from p537/7 mice, as host cells. One concern is whether human p53 functions in the regulation of mouse centrosome duplication. Previous studies have shown that a variety of transactivation mutant human p53 could cooperate with activated ras oncogene to transform rat embryonic ®broblasts (Crook et al., 1994; Kikuchi-Yanoshita et al., 1995) . Moreover, a conservation of essential components of centrosomes has been demonstrated: heterologous centrosomes from sea urchin, mouse, human and calf, all successfully duplicate in Xenopus eggs when injected (reviewed in Bornens, 1992) . Thus, we predicted that the centrosome duplication regulatory function of human p53 would be exerted in mouse cells.
Both R175H and R249S are transactivation-negative, hence the expression of these mutants are not expected to aect cell viability (Crook and Vousden, 1992) . We, thus, stably transfected R175H and R249S mutants into p537/7 MEFs along with a plasmid containing a hygromycin (Hyg)-resistance gene as a selection marker. As a control, a vector was transfected. Vector-, R175H-, and R249S-transfection all gave rise to similar number of Hyg-resistant colonies, con®rming that expression of R175H or R249S does not interfere with cell viability. Several Hyg-resistant colonies were sub-cloned, and examined for the expression of transfected p53 mutants by immunoblot analysis using antibody speci®c to human p53 ( Figure  1 ). We selected two cell lines from each transfection that expressed equivalent amounts of p53 [p537/7 (R175H)-1, p537/7(R175H)-2, p537/7(R249S)-1, and p537/7(R249S)-2, respectively). One vectortransfected cell line (p537/7 Vec) was also maintained for further experimentation.
Since both S315A and S315D mutants are known to retain a wild-type transactivation function (Crook et al., 1994; Fuchs et al., 1995) , high level expression of these mutants are expected to result in either cell cycle arrest or apoptosis (recently reviewed in Bates et al., 1999) . To circumvent this problem, we decided to use an inducible expression system for S315A and S315D mutants. We had previously generated a tetracycline (Tet)-inducible`Tet-on' expression system in p537/7 MEFs (Tarapore et al., 2001) . In these cells, expression of a gene placed under a Tet-promoter (pTRE vector) is`turn on' by addition of doxycycline (Dox). The Teton p537/7 MEFs were transfected with each of the pTRE-plasmids containing mutant as well as wild-type p53 together with a plasmid encoding a Hyg-resistance gene as a selectable marker. As a control, a pTRE vector was transfected. The Hyg-resistant colonies were subcloned, and screened for induced expression of p53 by immunoblot analysis using anti-human p53 antibody (Figure 2) . We selected one cell line from each transfection, designated as p537/7Tet(wt), p537/7 Tet(S315A) and p537/7Tet(S315D) respectively, which showed virtually no expression under an uninduced state (Figure 2, lanes 3, 5 and 7 ), but showed detectable levels of p53 expression in the presence of Dox (lanes 4, 6 and 8). One pTRE vectortransfected cell line [p537/7pTRE(Vec)] was also maintained as a control.
Since S315D and S315A as well as wild-type p53 all retain anti-proliferative activities, we tested the cell cycling (S phase entry) of p537/7Tet(S315A), p537/7Tet(S315D), and p537/7Tet(wt) cells during Dox-treatment. These cells were maintained in the presence of Dox for 2 weeks. Dox-treated and untreated cells were then BrdU-labeled for 2 h, and then immunostained with anti-BrdU monoclonal antibody. There was no signi®cant dierence in the rate of BrdU-incorporation during the 2 h-labeling period (*30%) between uninduced and induced cells for p537/7 Tet(wt), p537/7Tet(S315A) and p537/7 Tet(S315D) cells (data not shown). Thus, low level expression of wild-type, S315A and S315D allows cells to undergo normal cell cycle progression, which is consistent with our previous observations (Tarapore et al., 2001) .
Effect of expression of the`hot spot' and CDK phosphorylation site mutants on the centrosome profile We examined whether expression of the p53 mutants in p537/7 MEFs aected centrosome behavior. Exponentially growing vector-transfected cells as well as cells expressing either R175H or R249S were immunostained for centrosomes using anti-g-tubulin antibody, and the number of centrosomes per cell was scored (Figure 3a) . The control vector cell line (p537/7(Vec)) showed the expected abnormal centro- Figure 1 Generation of p537/7 MEFs expressing either R175H or R249S p53 mutant. Extracts prepared from p537/7 MEFs subcloned after transfection with a vector plasmid (p537/7(Vec)), R175H [p537/7(R175H)-1 and -2], and R249S (p537/7 (R249S)-1 and -2) were subjected to immunoblot analysis using anti-human p53 monoclonal antibody (mixture of clones1801 and DO-1, upper panel). The SDS ± PAGE gel loaded with equal amounts of the samples was run in parallel, and probed with antia-tubulin monoclonal antibody (clone DM1A, lower panel) as an internal control Figure 2 Generation of p537/7 MEFs with inducible expression of wild type and mutant p53 proteins. Extracts were prepared from p537/7Tet(Vec), p537/7Tet(S315A), p537/7 Tet(S315D), and p537/7Tet(wt) cells, which had been growing exponentially in the presence (+) and absence (7) of Doxycycline (Dox) for 4 days. The extracts were subjected to immunoblot analysis using anti-p53 monoclonal antibody (mixture of clones 1801 and DO-1, upper panel). The same blot was re-probed with anti-a-tubulin polyclonal antibody as a loading control (lower panel) Figure 3 Centrosome pro®les of p537/7 MEFs expressing wild-type and mutant p53 proteins. (a) Exponentially growing p537/7(Vec) control cell line, two p537/7(R175H) cell lines and two p537/7(R249S) cell lines were immunostained with anti-gtubulin antibody, and the number of centrosomes per cell was scored under a¯uorescence microscope. For each cell line, 4200 cells were examined. The data are presented as average+standard error determined from three separate experiments. (b) Dox-treated (for 2 weeks; +Dox) and untreated (7Dox) p537/7Tet(Vec), p537/7Tet(wt), p537/7Tet(S315A) and p537/7Tet(S315D) cells were immunostained with anti-g-tubulin antibody, and the number of centrosomes per cell was scored as described in (a). (c) To con®rm that the doublets detected by anti-g-tubulin antibody were two duplicated intact centrosomes, and not physically separated centriole pair, co-immunostaining with anti-g-tubulin polyclonal and anti-a-tubulin monoclonal (DM1A) antibodies after cold treatment and brief extraction was performed. The representative images of the centrosomes (centrioles) immunostained with anti-gtubulin antibody (panels a, d and g) and anti-a-tubulin antibody (panels b, e and h) are shown. Cells were also counterstained with DAPI (panels c, f and i). Panels a', b', d', e', g' and f' show the magni®ed images of the indicated area in the corresponding images. Panels c', f' and i' show the overlaid images of panels a' and b', d' and e', and g' and h', respectively. Panels a ± c and a' ± c' show unduplicated centrosome of a p537/7(R249S)-1 cell, and panels d ± f and d' ± f' shows duplicated centrosomes of a p537/7 (R249S)-1 cell. Panels g ± i and g' ± i' shows hyperampli®ed centrosomes of a p537/7(R175H)-1 cell. Scale bar, 10 mm some pro®le with 21% of cells with one centrosome, 54% with two centrosomes, and 25% with 53 centrosomes. Expression of R175H mutant exacerbated the abnormal centrosome pro®le as seen in both p537/7(R175H)-1 and p537/7(R175H)-2 lines with a decrease in the per cent of cells with one centrosome (12 ± 13%), and an increase in the per cent of cells with 53 centrosomes (34 ± 37%). The`gain-of-function' property of R175H in centrosome hyperampli®cation has recently been reported also by Wang et al. (1998) and Murphy et al. (2000) . In contrast, expression of R249S greatly restored the centrosome numerality with an increase in the per cent of cells with one centrosome (40 ± 46%), and a decrease in the per cent of cells with 53 centrosomes (5 ± 6%), which is similar to normal p53+/+ MEFs (Fukasawa et al., 1996) . Thus, among the`hot spot' mutants, certain mutant(s) have lost, while some at least partially retain the ability to regulate centrosome duplication.
In the uninduced (7Dox) state, p537/7pTRE(-Vec), p537/7pTRE(wt), p537/7 Tet(S315A) and p537/7Tet(S315D) cells all displayed the ampli®ed centrosome pro®le with 21 ± 25% of the cells with one centrosome and 17 ± 19% with 53 centrosomes ( Figure   Figure 4 Wild-type p53 associates with the centrosomes. (a) Dox-treated (for 2 weeks) p537/7Tet(Vec) (panels a ± d) and p537/7Tet(wt) (panels e ± h) were immunostained with anti-g-tubulin polyclonal (panels a, e and i) and anti-p53 monoclonal (mixture of clones 1801 and DO-1) (panels b, f and j) antibodies. The antigen-antibody complexes were detected by rhodamineconjugated goat anti-mouse IgG and FITC-conjugated goat anti-rabbit IgG antibodies. Panels c, g and k show DAPI staining. Panels d, h, and l show the overlay of panels a ± c, e ± g, and l ± k, respectively. The arrows point to unduplicated centrosomes, while arrowheads point to duplicated centrosomes. Panels a ± h show interphase cells, and panels i ± l show a mitotic cell. Scale bar, 20 mm. (b) Statistical analysis of centrosomal association of wild-type p53. To dierentiate unduplicated and duplicated centrosomes, we selectively examined cells with either one (unduplicated) centrosome or two juxtapositioned (duplicated) centrosomes. For both unduplicated and duplicated centrosomes, 4300 cells were examined. For the data presentation, the number of cells (with either unduplicated or duplicated centrosomes) that were examined was set as 100% 3b, top panels), similar to the pro®le of p537/7 MEFs previously reported (Fukasawa et al., 1996) . To evaluate the eect of S315A and S315D expression on the centrosome pro®le, cells were maintained in the presence of Dox for 2 weeks. Since p537/7 cells continuously undergo cell death due to mitotic defects resulting from centrosome hyperampli®cation, 2-week induction period was previously determined to be sucient for enrichment of cells that had potentially regained the control of centrosome duplication by induced expression of p53 (Tarapore et al., 2001) . The Dox-treated cells were subjected to immunostaining with anti-g-tubulin antibody (Figure 3b , bottom panels). p537/7pTRE(Vec) cells showed the centrosome pro®le similar with that under an uninduced state, indicating that Dox-treatment does not aect centrosome behavior. As previously shown (Tarapore et al., 2001) , induced expression of wild-type p53 almost completely restored the normal centrosome pro®le. Induced expression of S315A non-phosphorylatable mutant results in partial restoration of centrosome pro®le with the increase in the per cent of cells with one centrosome from 23 to 47%, and the decrease in the per cent of cells with 53 centrosomes from 19 to 10%. More pronounced restoration was observed in cells expressing S315D, which mimics the constitutively phosphorylated form of p53, evidenced by a marked increase in per cent of cells with one centrosome from 21 to 46% and a decrease in per cent of cells with 53 centrosomes from 18 to 5%. These results suggest that phosphorylation of Ser 315 is involved in the regulation of the centrosome duplication cycle.
To con®rm that each anti-g-tubulin-reactive signal represented an intact centrosome with a pair of centrioles, cells were also examined for centrioles by immunostaining with anti-a-tubulin antibody. a-tubulin is one of the major components of centrioles, hence immunostaining of a-tubulin after removal of microtubules nucleated from centrosomes by cold treatment and brief extraction allows visualization of the centriole pair within the centrosome at a high magni®cation (see Materials and methods). Cells were co-immunostained for g-and a-tubulins. Each signal (single and double dots) detected by anti-g-tubulin antibody were resolved to a pair of dots by a-tubulin immunostaining, which represented a centriolar pair (Figure 3c , panels a ± f; magni®ed images, panels a' ± f'). We also con®rmed the integrity of the hyperampli®ed signals detected by anti-g-tubulin antibody [representative images of p537/7(R175H) cells are shown in Figure 3c , panels g ± i; magni®ed images, g' ± h'). The centrosome pro®les of p537/7(R175H), p537/7 (R249S), p537/7Tet(S315A) and p537/7Tet(S315D) cells determined by immunostaining of centrioles were found to be similar to those determined by g-tubulin immunostaining (data not shown).
Characterization of the centrosome binding activity of wild-type and mutant p53
Since some cytoplasmic p53 proteins are known to localize to the centrosomes (Blair Zajdel and Blair, 1988; Brown et al., 1994) , we sought to determine whether ectopically expressed human p53 retained the centrosome binding activity. The p537/7Tet(wt) cells that contain a Tet-inducible wild-type p53 were cultured under an optimal growth condition in the presence of Dox for 2 weeks. To enhance the visualization of p53 localized to centrosomes, cells were brie¯y extracted with detergent prior to ®xation (see Materials and methods). Cells were then coimmunostained with anti-g-tubulin polyclonal and anti-p53 monoclonal antibodies ( Figure 4a) . As a control, p537/7Tet(Vec) cells were immunostained, which showed no non-speci®c staining of p53 (panel b). Although induced expression of wild-type p53 in p537/7 cells results in a similar centrosome pro®le with normal cells, there are a minor population of cells (*5%) with hyperampli®ed centrosomes. To dierentiate unduplicated and duplicated centrosomes, we examined the cells with either one or two centrosomes. However, the presence of two centrosomes does not necessarily confer duplicated centrosomes in p537/7 cells: they may be unduplicated centrosomes inherited from mother cells with hyperampli®ed centrosomes upon cytokinesis. To circumvent this problem, we speci®cally examined the cells with two juxtapositioned centrosomes for duplicated centrosomes, since duplicated centrosomes typically position next to each other, while multiple unduplicated centrosomes inherited from mother cells usually scatter around the nucleus. In interphase p537/7Tet(wt) cells, we observed that the induced wild-type p53 associated with both unduplicated (panels e ± h, indicated by arrows) and duplicated centrosomes (panels e ± h, indicated by arrowheads). Moreover, wild-type p53 associated with centrosomes (spindles poles) during mitosis (panels i ± l, indicated by arrows). These observations are consistent with the previous studies examining endogenous mouse wild-type p53 (Blair Zajdel and Blair, 1988; Brown et al., 1994) . Further statistical analysis of centrosomal association of wildtype p53 revealed that not all unduplicated centrosomes were bound by p53; p53 was not detected in *30% of unduplicated centrosomes (Figure 4b ). In contrast, p53 was detected in all of the duplicated centrosomes. Considering that p53 associates with centrosomes during mitosis, p53 either (1) dissociates from centrosomes before the start of the new cell cycle and reassociates at a certain time point in G1, or (2) undergoes dynamic centrosomal dissociation and reassociation during G1 progression. We next examined the centrosomal localization of the mutant p53 proteins. Exponentially growing p537/7(R175H)-1 and p537/7(R249S)-1 as well as Dox-treated (for 2 weeks) p537/7Tet(S315A) and p537/7Tet(S315D) cells were co-immunostained for g-tubulin and p53 proteins. The results are summarized in Table 1 , and the representative immunostainings are shown in Figure 5 . Similar to wild-type p53, all of the p53-mutants were localized to duplicated centrosomes. Figure 5 Dierent centrosome-binding properties of R175H and R249S mutants. p537/7(R175H)-1 (panels a1 ± a4 & b1 ± b4) and p537/7(R249S)-1 (panels c1 ± c4 & d1 ± d4) as well as Dox-treated (for 2 weeks) p537/7Tet(S315A) (panels e1 ± e4 & f1 ± f4) and p537/7Tet(S315D) (panels g1 ± g4 & h1 ± h4) were immunostained with anti-g-tubulin polyclonal antibody (panels a1 ± h1) and anti-p53 monoclonal antibodies (mixture of clone 1801 and DO-1) (panels a2 ± h2), and detected by rhodamine-conjugated antimouse IgG and FITC-conjugated anti-rabbit IgG antibodies. Panels a3 ± h3 show DAPI staining. Panels a4 ± h4 show overlaid images. The arrows point to unduplicated centrosomes, while arrowheads point to duplicated centrosomes. Scale bar, 10 mm Oncogene Differential effect of various p53 mutants on centrosome duplication P Tarapore et al R249S and S315D were also found at unduplicated centrosomes (panels c2 and g2). However, R175H and S315A failed to bind to unduplicated centrosomes (panels a2 and e2). Statistical analysis of the unduplicated centrosome-associating properties of R249S and S315D showed that similar to wild-type p53, both mutants were not detected in *30% of unduplicated centrosomes (data not shown). Taken together, among mutant p53 proteins, there is a dierence in the centrosome-binding activity. When p53's unduplicated centrosome-binding activity and eect on the centrosome pro®les were compared, it is clear that the mutant p53 protein that retains the ability to bind to unduplicated centrosomes (i.e., Figure 6 Levels of Waf1 in the p537/7 MEFs expressing p53 mutant proteins. (a) Extracts were prepared from p537/7(Vec), p537/7(R175H)-1 and p537/7(R249S)-1 cells, and were run on SDS ± PAGE, followed by immunoblot analysis using anti-Waf1 polyclonal antibody (Ab-5 Calbiochem, upper panel). The control gel run in parallel was loaded with equal amounts of the samples, and subjected to immunoblot analysis using anti-a-tubulin monoclonal antibody (lower panel). (b) p537/7Tet(Vec), p537/7 Tet(wt), p537/7Tet(S315A) and p537/7Tet(S315D) cells were cultured either in the presence or absence of Dox for 2 weeks, and cell extracts were prepared. As an additional control, the extracts were prepared from primary wild-type (p53+/+) skin ®broblasts (MSFs, passage 3) from a littermate of p537/7 mice. The reason of the use of skin ®broblasts as a control instead of MEFs is that p53+/+ MSFs proliferate without any signs of crisis for 410 passages, while senescence and cell death can be detected in p53+/+ MEFs as early as passage 3. Thus, Waf1 that is implicated in cell cycle arrest may be up-regulated in those senesced or dead/dying p53+/+ MEFs, which may misrepresent the physiological levels of Waf1 of normal proliferating cells. Indeed, when Waf1 levels were compared between wild-type MEFs and MSFs (passage 4), we detected slightly higher levels of Waf1 in MEFs than in MSFs (data not shown). The extracts were run on SDS ± PAGE, and subjected to immunoblot analysis for Waf1 and a-tubulin (control) as described in (a) Figure 7 Centrosome re-duplication capacity of Aph-treated cells expressing mutant p53 proteins. (a) p53+/+ MEFs, p537/7 (Vec), p537/7(R175H)-1 and p537/7(R249S)-1 cells were Aph-treated for 36 h. Cells were then immunostained with anti-gtubulin antibody, and the number of centrosomes per cell was scored under a¯uorescence microscope. For each cell line, 4200 cells were examined. The data are shown as average+standard error determined from three separate experiments. One experiment was performed by co-immunostaining with anti-g-tubulin polyclonal and anti-a-tubulin monoclonal antibodies after cold treatment and brief extraction as described in the legend to Figure 3 , which gave similar results (data not shown). (b) The Dox-treated (2 weeks) p537/7Tet(S315A), p537/7Tet(S315D), p537/7Tet(wt), and the control p537/7Tet(Vec) cells were treated with Aph for 36 h (Dox-treatment was continued during Aph-treatment). Cells were then examined for the centrosome re-duplication capacity as described in (a) R249S and S315D) leads to more pronounced restoration of the centrosome pro®le than those that have lost the binding activity to unduplicated centrosomes (i.e., R175H and S315A). This suggests that the ability to bind to unduplicated centrosomes may be important for the p53's overall regulation of centrosome duplication. Moreover, the S315A fails to associate with unduplicated centrosomes, while S315D binds to unduplicated centrosomes, suggesting that the phosphorylation at Ser 315 is essential for p53 to associate with unduplicated centrosomes.
The transactivation function of p53 and the regulation of centrosome duplication
We have previously shown that Waf1 plays a partial role in the p53-mediated control of centrosome duplication (Tarapore et al., 2001) . We, thus, determined the Waf1 expression in all of the mutant p53-expressing cell lines. Cell lysates prepared from p537/7(Vec), p537/7(R175H)-1 and p537/7 (R249S)-1 cells as well as Dox-treated and untreated p537/7Tet(Vec), p537/7Tet(S315A) and p537/7 Tet(S315D) cells were subjected to immunoblot analysis for Waf1 (Figure 6a,b) . As controls, mouse skin ®broblasts derived from the wild-type p53 littermates (p53+/+MSFs) as well as p537/7Tet(wt) were included. Only low levels of Waf1 were detected in p537/7(Vec), p537/7(R175H)-1 and p537/7 (R249S)-1 cells (Figure 6a, lanes 1 ± 3) , indicating that both R175H and R249S mutants are unable to transactivate Waf1 as shown previously (Crook et al., 1994) . All p537/7Tet(Vec), p537/7Tet(S315A) and p537/7Tet(S315D) cells under an uninduced state showed low levels of Waf1 expression (Figure 6b, lanes  1, 3, 5 ). After induction, there was a readily detectable increase in Waf1 expression in both p537/7 Tet(S315A) and p537/7Tet(S315D) cells (lanes 4 and 6). In contrast, no increase in Waf1 expression was detected in p537/7Tet(Vec) cells (lane 2). The levels of Waf1 up-regulated by induced expression of S315A and S315D, however, were similar to the levels of Waf1 physiologically present in p53+/+MSFs (lane 7) and in the Dox-treated p537/7Tet(wt) cells (lane 9). Thus, Figure 8 Dierence in the frequency of mitotic defects and the degree of chromosome instability between R175H-and R249S-expressing cells. (a and b) Exponentially growing p537/7(R175H)-1 and p537/7(R249S)-1 cells were probed with anti-g-tubulin polyclonal and anti-a+b-tubulin monoclonal (DM1A+Tub.2.1) antibodies. Antigen-antibody complexes were detected with FITCconjugated goat anti-rabbit IgG and rhodamine-conjugated goat anti-mouse IgG antibodies. Cells were counterstained with DAPI. Mitotic cells readily identi®ed by their condensed chromosomes under a microscope were examined for the frequency of multipolar (in comparison to bipolar) spindle formation (a). The experiments were performed twice, yielding almost identical results. The data presented in (a) are the average of the two experiments, demonstrating that the expression of R175H mutant resulted in a higher frequency of aberrant spindle formation than R249S. The representative immunostaining of mitotic cells are shown in (b), in which centrosomes (spindle poles) are shown in green, microtubules (mitotic spindles) in red, and chromosomes in blue. (c) Giemsa-stained metaphase spreads prepared from p537/7(R175H)-1 and p537/7(R249S)-1 cells were examined under a microscope for the number of chromosomes per cell. Total 100 metaphase spreads for each cell line were examined. Because of the diculties of this procedure as described in the text, we allowed +3 deviation for chromosome counting. While majority of p537/7(R249S)-1 cells fall into between 45 and 72 chromosomes, metaphase spreads of p537/7(R175H)-1 show extensive deviations the partial restoration of the centrosome pro®le by induction of S315A mutant may be attributed to its ability to up-regulate Waf1, and S315D exerts additional Waf1-independent centrosome duplication regulatory activity.
Effect of p53 mutations on centrosome re-duplication
It had been shown that centrosomes continuously reduplicate in cells arrested at G1/S by either aphidicolin (Aph) or hydroxyurea-treatment (Balczon et al., 1995) . We have recently shown, however, that this centrosome re-duplication occurs only in the absence of wild-type p53: in the Aph-treated wild-type MEFs and p53-null MEFs that ectopically express wild-type p53, the centrosome does not undergo re-duplication (Tarapore et al., 2001) . Based on these observations, we examined the eects of each mutant p53 on the centrosome reduplication in p537/7 cells arrested at G1/S. p537/7(Vec), p537/7(R175H)-1 and p537/7 (R249S)-1 cells were Aph-treated for 36 h, and the number of centrosomes per cell was analysed ( Figure  7a ). As previously shown, a signi®cant increase in the number of cells with 53 centrosomes (*60%) was observed in the control p537/7(Vec) cells, demonstrating the occurrence of centrosome re-duplication. Expression of R175H showed no eect on the centrosome re-duplication capacity of p537/7 cells, exhibiting the similar centrosome pro®le with that of the control p537/7(Vec) cells. However, partial suppression was observed in cells expressing R249S as evidenced by the decrease in the number of cells with 53 centrosomes (*40%).
To examine the eect of S315A and S315D, p537/7 Tet(S315A), p537/7Tet(S315D), and p537/7Tet(wt) cells as well as the control p537/7Tet(Vec) cells were ®rst maintained in the presence of Dox for 2 weeks. Cells were then treated with Aph for 36 h in the presence of Dox, and the number of centrosomes per cell was analysed (Figure 7b) . Expectedly, the control p537/7Tet(Vec) cells show the occurrence of centrosome re-duplication at a similar frequency with p537/7(Vec) cells (Figure 7a ). Induced expression of S315A resulted in a signi®cant reduction of the number of cells with 53 centrosomes (*30%), suggesting that S315A mutant partially retains the ability to suppress centrosome re-duplication. However, we detected more pronounced suppression in the cells expressing S315D mutant with a reduction in the number of 53 centrosomes to *15%, which is similar to that observed in p537/7(Tet) cells expressing physiological level of wild-type p53 upon induction seen in p537/7Tet(wt) cells. Taken together, transactivation function, ability to bind to the unduplicated centrosomes, and phosphorylation of Ser 315, all appear to be involved in the suppression of centrosome re-duplication.
Chromosome instability in cells expressing mutant p53
Centrosome hyperampli®cation results in mitotic defects and extensive chromosome instability (Fukasawa et al., 1997; Carroll et al., 1999) . The ®nding that R175H mutant has lost the centrosome duplication regulatory activity, while R249S partially retains the ability to control centrosome duplication, suggest that these`hot spot' p53 mutants may induce dierent degrees of chromosome instability. To test this hypothesis, we ®rst examined the frequency of mitotic defect (formation of multipolar spindles instead of normal bipolar spindles) in p537/7(R175H)-1 cells, p537/7(R249S)-1 cells, and p537/7(Vec) cells (control) by immunostaining with anti-g-tubulin polyclonal antibody (centrosomes) and anti-a+b tubulin monoclonal antibodies (mitotic spindles). Consistent with the previous studies (Chiba et al., 2000) , *30% of mitotic p537/7(Vec) cells contained abnormal spindles (data not shown). As expected, defective mitoses were detected at a higher frequency in cells expressing R175H (*35%) than those expressing R249S (*15%) (Figure 8a , representative immunostaining of abnormal and normal bipolar mitotic spindles were shown in Figure 8b ).
We next examined the extent of aneuploidy in p537/7(Vec), p537/7(R175H)-1 and p537/7 (R249S)-1 cells. The Giemsa-stained metaphase chromosome spreads were directly analysed under a microscope (Figure 8c ). In this experimental procedure, there is unavoidable background noise that interferes with accurate scoring, including contamination of free chromosomes of other ruptured mitotic cells, and masking of smaller chromosomes by larger ones. To compromise the background noise and to examine statistically signi®cant numbers of metaphase spreads at the same time, we allowed +3 deviation in the chromosome number (n) ranging from n531 to n4107 (Figure 8c ). As previously shown for p537/7 cells (Chiba et al., 2000) , p537/7(Vec) cells showed extensive deviation in the chromosome number per cell (data not shown). Consistent with the degree of centrosome abnormality and the frequency of defective mitosis, extensive chromosome instability was observed in the p537/7(R175H)-1 cells (upper panel) at a level similar to p537/7(Vec) cells. In contrast, in the p537/7(R249S)-1 cells, the number of chromosomes was much less deviated from each other. These results demonstrate that R175H and R249S mutants induce dierent degrees of chromosome instability. Discussion p53 regulates centrosome duplication in part through transactivation of Waf1: reintroduction of wild-type p53 into p537/7 cells restores the normal centrosome duplication cycle, while only partial restoration is achieved by introduction of Waf1 (Tarapore et al., 2001) . Thus, p53 must invoke additional Waf1-independent regulatory pathways. In this study, we tested several p53 mutants for the ability to control centrosome duplication. Missense mutation at the residue 175 and 249 is frequently observed in cancer cells, and is shown to abolish the transactivation function of p53 (Crook et al., 1994) . The`hot spot' mutants (R175H and R249S) were expressed in p537/7 cells, and examined for the eect on the centrosome duplication cycle through two dierent assay systems. One is to examine a centrosome pro®le during exponential growth. Because the centrosome normally initiates duplication at late G1, the centrosome pro®le of wild-type cells typically shows 40 ± 60% of cells with one centrosome and 40 ± 60% with two centrosomes. However, since loss of p53 results in premature initiation of centrosome duplication as well as centrosome re-duplication within a single cell cycle, the centrosome pro®le of p537/7 cells shows a decreased number of cells with one centrosome (*20%), an increased number of cells with two centrosomes (50 ± 60%) and with 53 centrosomes (20 ± 30%) (Fukasawa et al., 1996) . We found that expression of R175H exacerbated the abnormal centrosome pro®le of p537/7 cells with a further decrease in the number of cells with one centrosome (*10%) and increase in the number of cells with 53 centrosomes (30 ± 40%). In contrast, expression of R249S resulted in substantial restoration of the centrosome pro®le. Thus, among the`hot spot' p53 mutants, there is a dierence in the ability to regulate the centrosome duplication cycle. This is further evidenced by the centrosome re-duplication assay, which is based on the fact that centrosomes continuously re-duplicate in cells arrested at G1/S by aphidicolin (Aph) (Balczon et al., 1995) . We have recently shown that the centrosome re-duplication capacity in Aph-arrested cells is under control of p53 (and partially Waf1). For instance, p537/7 cells show continuous reduplication of centrosomes during arrest, while re-introduction of wild-type p53 almost completely blocks re-duplication. In addition, re-introduction of Waf1 only partially blocks re-duplication (Tarapore et al., 2001) . We found that expression of R175H failed to block centrosome re-duplication in the Aph-treated p537/7 cells, while expression of R249S partially suppressed re-duplication. Since both R175H and R249S mutants are transactivation negative, these observations strongly suggest the presence of other transactivation-independent pathways, by which p53 controls centrosome duplication.
We found that R175H and R249S mutants dier in their centrosome binding properties. R249S binds to both unduplicated and duplicated centrosomes, similar to wild-type p53. In contrast, R175H binds only to duplicated, but not unduplicated centrosomes. Although both Arg175 and Arg249 residues lie within the central DNA binding domain, these residues do not directly contact the DNA, but are important for stabilizing the proper folding of the DNA binding domain (Cho et al., 1994) . Thus, loss of DNA binding activity results, when these sites are mutated. NMR spectroscopic analysis has revealed that R249S mutation induces only localized structural changes in the proximity of the site of mutation, hence the overall structure of R249S is similar to that of wild-type p53 (Wong, et al., 1999) . In contrast, R175H mutation has been shown to induce a gross conformational change. For instance, the DNA binding core domain becomes highly sensitive to proteases when R175H mutation is present, suggesting that R175H mutation results in an unfolded structure, making this region more susceptible to proteases (Cho et al., 1994) . These structural dierences induced by dierent mutations may explain the dierence in the centrosome binding property between R175H and R249S.
The dierent centrosome-binding activities of R175H and R249S raise the possibility that association of p53 with unduplicated centrosomes might be critical for the overall p53-mediated regulation of centrosome duplication. This prediction was supported by the studies using Ser 315 phosphorylation site mutants. Ser 315 of p53 is known to be phosphorylated by CDK2/cyclin E as well as CDK2/cyclin A (Price et al., 1995; Wang and Prives, 1995) , both of which are implicated in the initiation of centrosome duplication (Lacey et al., 1999; Hinchclie et al., 1999 , Meraldi et al., 1999 . We found that the non-phosphorylatable S315A mutant binds to duplicated centrosomes, but failed to bind to unduplicated centrosomes. In contrast, the S315D mutant, which mimics a constitutively phosphorylated form, binds to both unduplicated and duplicated centrosomes. Thus, the phosphorylation of Ser 315 appears to be essential for association of p53 with unduplicated centrosomes. We further found that re-introduction of S315D into p537/7 cells resulted in more pronounced restoration of the centrosome duplication cycle than S315A in both the centrosome pro®le and suppression of centrosome re-duplication during Aph-mediated arrest. Since both S315A and S315D are transactivation positive (i.e., up-regulation of Waf1), these results con®rm that p53 regulates centrosome duplication through both transactivation (or Waf1)-dependent and -independent manners.
It has been known that chromosome instability (aneuploidy) is a signi®cant prognostic marker for more aggressive characteristics in various tumors (reviewed in Williams and Daly, 1990; Ahnen, 1992; Vet et al., 1994) . This is probably related to the ®nding that chromosomal loss and/or gain exceedingly increases the mutation rate, and thus facilitates acquisition of further malignant phenotypes. The dierence in the ability to control centrosome duplication among the`hot spot' mutants suggests that there may be dierence in the degree of pro-carcinogenic activity among the`hot spot' mutants. Indeed, signi®cantly more mitotic defects due to the presence of multiple mitotic spindles were observed in p537/7 cells expressing R175H than those expressing R249S. Accordingly, more pronounced chromosome destabilization was observed in the R175H-expressing cells than in the R249S-expressing cells. The previous studies have shown an accelerated tumor progression in p537/7 mice expressing mutant p53 equivalent to R175H than the parental p537/7 mice (Wang et al., 1998; Liu et al., 2000) . Moreover, clinical studies revealed a high correlation of R175H mutation and poor prognosis in human cancer (Aas et al., 1996) . The ®ndings presented in our study raises the possibility that the`gain-of-function' of the R175H mutant in carcinogenesis may be attributed to further destabilization of chromosomes by exacerbating the centrosome abnormality. At present, the mechanism of how R175H acts as a`gain-of-function' mutant in centrosome homeostasis is unknown. In addition, the molecular basis of the failure of R175H as well as S315A to bind to unduplicated centrosomes remains to be elucidated. Much of the molecular changes during centrosome duplication are presently unknown, and further identi®cation and characterization of centrosomal components during the cell cycle will certainly shed light on these issues. Nevertheless, considering that the presence of p53 mutations may potentially serve as a marker to predict the tumor outcome (reviewed in Elledge and Allred, 1998; Ozen and Hall, 2000; Nylander et al., 2000) , it is of great importance to analyse other`hot spot' mutants for their ability to regulate centrosome duplication, which is currently undertaken in our laboratory.
Materials and methods
Cells
p537/7 MEFs were maintained in complete medium (DMEM supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (100 mg/ml)), and grown in an atmosphere containing 10% CO 2 .
Plasmids and transfection
For generation of cell lines expressing R175H or R249S human p53 mutants, p537/7 MEFs were transfected by the calcium phosphate procedure, with an eukaryotic expression plasmid encoding either R175H or R249S together with a plasmid harboring a hygromycin (Hyg)-resistance gene at 20 : 1 molar ratio. The Hyg-resistant colonies arisen in the media containing Hyg (100 mg/ml) were sub-cloned, and examined for expression of p53.
The plasmids for inducible expression were constructed in a pTRE vector, which uses the rtTA binding site promoter to drive expression (Gossen et al., 1995) . The full-length wild-type and mutant human p53 cDNAs were cloned into pTRE as EcoRI ± BamHI fragments to yield pTRE-p53 plasmids. The inducible expression system was established in two steps. First, the pUHD172-1neo expression vector encoding rtTA and a plasmid encoding puromycin (Puro)-resistant gene (pBABE-puro) were co-transfected into p537/7 MEFs. Puro-resistant colonies arisen in the media containing Puro (2 mg/ml) were sub-cloned. The clone which showed the appropriate level of rtTA expression with minimal background noise was selected (Tet-on p537/7 cells). Next, we transfected the Tet-on p537/7 cells with a plasmid encoding human pTRE-p53/wt, pTRE-p53/S315A, pTRE-p53/S315D or the empty vector pTRE (as a negative control) together with a plasmid encoding Hyg-resistance gene as a selectable marker. The colonies formed 2 weeks after transfection in the media containing Hyg (100 mg/ml) were sub-cloned. The cell lines that expressed transfected p53 in the presence of Dox (1 ± 4 mg/ml) at a level which allowed continuous cell cycling were selected (p537/7Tet (wt), p537/7Tet(S315A) and p537/7Tet(S315D)), and maintained for further experimentation.
Immunoblot analysis
Cells were washed twice in PBS and lysed in SDS-NP-40 lysis buer (1% SDS, 1% Nonidet P-40 (NP-40), 50 mM Tris (pH 8.0), 150 mM NaCl, 4 mM Pefabloc SC (Boehringer Mannheim), 2 mg/ml leupeptin, 2 mg/ml aprotinin). The lysates were brie¯y sonicated, boiled for 5 min, and then cleared by a 10 min centrifugation at 20 000 g at 48C. The supernatant was further denatured at 958C for 5 min in sample buer (2% SDS, 10% glycerol, 60 mM Tris (pH 6.8), 5% b-mercaptoethanol, 0.01% bromophenol blue). Samples were resolved by SDS ± PAGE, and fractionated proteins were transferred to Immobilon-P (Millipore) sheets. The blots were incubated in blocking buer (5% (wt/vol) nonfat dry milk in Tris-buered saline+Tween 20 (TBS-T)) for 1 h and then primary antibody for 1 h at room temperature. The blots were then rinsed in TBS-T and incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The blots were rinsed in TBS-T, and the antibody-antigen complex was visualized by ECL chemiluminescence (Amersham) according to the manufacturer's instructions.
Indirect immunofluorescence
For co-immunostaining of g-tubulin and p53, cells grown on coverslips were washed twice with phosphate-buered saline (PBS) and brie¯y extracted with 0.1% Triton-X100 for 30 s. Cells were then washed twice with PBS, and ®xed with 10% formalin/10% methanol for 20 min at room temperature. The cells were then permeabilized with 1% NP-40 in PBS for 5 min, and incubated with blocking solution (10% normal goat serum in PBS) for 1 h at room temperature. Cells were then probed with rabbit anti-g-tubulin polyclonal antibody and mouse anti-p53 monoclonal antibodies (mixture of clones DO1 and 1801) for 1 h. The antibody-antigen complexes were detected with rhodamine-conjugated goat anti-mouse IgG antibody and FITC-conjugated goat anti-rabbit IgG antibody (Boehringer Mannheim) by incubation for 1 h at room temperature. The samples were washed three times with TBS after each incubation, and then counterstained with 4',6-diamidino-2-phenylindole (DAPI) DNA dye.
For examination of centriole pairs within centrosomes by co-immunostaining of a-and g-tubulins, cells were ®rst placed on ice for 30 min to destabilize microtubules nucleated at the centrosomes. The cold-treated cells were then subjected to brief extraction (*30 s) with cold extraction buer (0.75% Triton X-100, 5 mM Pipes, 2 mM EGTA (pH 6.7)), brie¯y washed in cold PBS, and ®xed with 10% formalin/10% methanol. Cells were immunostained with anti-a-tubulin monoclonal (DM1A) and anti-g-tubulin polyclonal antibodies. The antibody-antigen complexes were detected with FITC-conjugated goat anti-rabbit IgG and rhodamineconjugated goat anti-mouse IgG antibodies.
